Jerusalem, Israel - November 27, 2014, Jerusalem, Israel - Teva Pharmaceutical Industries Ltd. announced that it has elected Yitzhak Peterburg as chairman, effective January 1, 2015.
Article continues below
Prof. Peterburg rejoined Teva’s Board of Directors in 2012. He was Teva’s Senior Vice President—Global Branded Products, in charge of innovative drugs, R&D and pipeline asset management from 2010-2011, after serving on Teva’s Board of Directors from 2009-2010.
Prof. Peterburg served as President and CEO of Cellcom Israel Ltd., a telecommunications enterprise in Israel, from 2003-2005. From 1997-2002, he served as CEO of Clalit Health Services, a healthcare provider (HMO) in Israel.
He led the digitizing of Clalit Health Services, including 100% Electronic Health Records (EHR) coverage and one of the first health information exchange systems in the world, and pioneered telemedicine in Israel.
Between 2000 and2002, he was a board member at the International Federation of Health Plans (iFHP) and vice-chairman of the Association International de la Mutualite (AIM).
Between 1990 and 1997, he held several managerial positions in the healthcare field, including CEO of the Soroka University Medical Center in Beer-Sheva. Prof. Peterburg currently serves as a director on the board of Rosetta Genomics Ltd.
Prof. Peterburg received an M.D. degree from Hadassah Medical School in 1977 and is board-certified in Pediatrics and Health Services Management. He received a Doctorate degree in Health Services Administration from Columbia University in 1987 and an M.Sc. degree in Information Systems from the London School of Economics in 1991.
Between 2009 and 2010, he served as Senior Fellow at the Milken Institute. He is a professor at the School of Business, Ben-Gurion University.
Prof. Peterburg, a member of the Board since 2012 and from 2009-2010, will succeed Phillip Frost, who previously announced plans to step down as Chairman by the end of the year.
Dr. Frost has also informed the Board that he will not stand for reelection as a director at the upcoming annual general meeting.
Additionally, the Board appointed Sol J. Barer as a director, also effective January 1, 2015.
Dr. Barer is Managing Partner at SJ Barer Consulting. From 1987-2011, he served in top leadership roles at Celgene Corporation, including as Executive Chairman (2010-2011), Chairman and CEO (2007-2010), CEO (2006-2010), President and Chief Operating Officer (1994-2006) and President (1993-1994).
Earlier in his career, he was a founder of the biotechnology group at the chemical company Celanese Corporation, which was later spun off as Celgene. Dr. Barer currently serves on the board of a number of other biotechnology companies, including Amicus Therapeutics and Aegerion Pharmaceuticals. He is Chairman of the Board of InspireMD and Medgenics. ■